Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by Janus Henderson Group PLC

Janus Henderson Group PLC lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 28.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,957 shares of the company’s stock after purchasing an additional 10,575 shares during the period. Janus Henderson Group PLC’s holdings in Intellia Therapeutics were worth $985,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of NTLA. Dimensional Fund Advisors LP increased its position in shares of Intellia Therapeutics by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock valued at $29,648,000 after buying an additional 98,865 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Intellia Therapeutics by 4.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company’s stock valued at $17,006,000 after acquiring an additional 37,714 shares during the period. Verition Fund Management LLC grew its position in shares of Intellia Therapeutics by 116.3% in the third quarter. Verition Fund Management LLC now owns 94,426 shares of the company’s stock valued at $1,940,000 after purchasing an additional 50,763 shares during the period. FMR LLC increased its stake in shares of Intellia Therapeutics by 5.0% during the third quarter. FMR LLC now owns 2,339,522 shares of the company’s stock worth $48,077,000 after purchasing an additional 111,104 shares in the last quarter. Finally, Thrivent Financial for Lutherans acquired a new position in shares of Intellia Therapeutics during the 2nd quarter worth about $679,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

NTLA opened at $12.90 on Friday. The stock has a market capitalization of $1.31 billion, a PE ratio of -2.37 and a beta of 1.76. Intellia Therapeutics, Inc. has a one year low of $12.47 and a one year high of $34.87. The business’s 50 day moving average price is $16.23 and its 200 day moving average price is $20.70.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to analyst estimates of $8.28 million. The business’s revenue for the quarter was down 24.1% on a year-over-year basis. During the same period last year, the company earned ($1.38) EPS. As a group, equities research analysts forecast that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NTLA has been the subject of several research reports. Stifel Nicolaus cut their price objective on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research note on Wednesday, September 11th. Canaccord Genuity Group reiterated a “buy” rating and set a $90.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Citigroup decreased their price objective on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a report on Friday, November 8th. Finally, Robert W. Baird decreased their price target on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.94.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the sale, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at $893,698.12. The trade was a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.20% of the stock is currently owned by corporate insiders.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.